CytomX expands leadership team with appointment of Michael Kavanaugh as chief scientific officer

5 January 2015

Oncology biotech company CytomX has appointed Michael Kavanaugh as chief scientific officer and head of research and early development.

The company has also appointed Sridhar Viswanathan as vice president of process sciences and manufacturing operations and Danielle Olander as vice president of human resources.

Prior to being appointed at CytomX, Dr Kavanaugh was senior vice president and chief scientific officer of Five Prime Therapeutics (Nasdaq: FPRX). Before this, he was vice president of Novartis Vaccines & Diagnostics (NOVN: VX).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK